Tecan Signals New Leadership Era
Tecan Group, recognized as a leader in laboratory automation, has shared its plans for a leadership transition that marks an exciting new chapter. Dr. Achim von Leoprechting has been a crucial figure in Tecan's growth for almost 12 years, with over six years as the CEO. As he approaches a new phase in his career, he has chosen to step down from his role, effective August 1, 2025, to embark on new projects while supporting the company in an advisory capacity.
Introducing Monica Manotas as New CEO
The Board of Directors has appointed Monica Manotas to succeed Dr. von Leoprechting, effective the same day. Having joined the Board in April 2024 and accumulated extensive experience in the life sciences sector, Ms. Manotas is already well-acquainted with Tecan's business dynamics.
Prior to joining Tecan's Board, Monica spent more than two decades at Thermo Fisher Scientific, where she honed her leadership skills in various executive roles. Her familiarity with the industry and innovative strategies positions her well to lead Tecan forward.
Planned Leadership Transition
The transition period will be handled delicately, ensuring that there is close collaboration between Dr. von Leoprechting and Ms. Manotas. This approach aims to maintain continuity and stability as Tecan continues its focus on growth and innovation.
Tecan's Financial Outlook
As part of its ongoing commitment to transparency, Tecan will present its financial results for the first half of 2025 on August 12, 2025. The company has anticipated a sales decline in local currencies during this period, but it remains confident regarding its financial outlook for the year. Tecan’s sustained growth and resilience, even amid fluctuating market conditions, strengthen its strategic position in the industry.
Reflection on Achievements and Future Goals
Dr. von Leoprechting expressed pride in Tecan's remarkable achievements during his tenure, which saw a growth of 60% since 2018. He emphasized that the company not only improved its financial standing but also fostered a vibrant company culture and embedded sustainability into its core strategy.
Comments on the Transition
Dr. Lukas Braunschweiler, Chairman of Tecan's Board, praised Dr. von Leoprechting's leadership and highlighted the importance of Monica Manotas' appointment as a continuation of Tecan's successful strategy. His comments reflect the expectation that under Monica's leadership, Tecan will innovate further while navigating the evolving landscape of life sciences.
Monica's Vision for Tecan
Feeling honored to take on the leadership role, Monica Manotas expressed her eagerness to guide Tecan towards achieving greater heights. Her excitement is rooted in her understanding of the needs within the life sciences sector and her commitment to fostering innovation and collaboration among the team. The goal is to ensure Tecan remains at the forefront of the industry while continuously delivering value to its stakeholders.
About Tecan
Founded in 1980, Tecan is a pioneer in laboratory automation solutions that facilitate global healthcare innovation. With over 3,000 employees and operations spanning Europe, North America, and Asia, Tecan is committed to enhancing healthcare through its innovative products and services. The company registered impressive sales of CHF 934 million in 2024 and is traded on the SIX Swiss Exchange under the ticker symbol TECN.
Future Milestones for Tecan
Looking ahead, Tecan is preparing for key upcoming events, including the release of their Interim Report on August 12, 2025, and a Q3 Qualitative Update scheduled for October 13, 2025. These reports will provide insight into Tecan's performance and strategic direction as it navigates the market.
Contact Information
For more details, interested parties can reach out to Martin Brändle, Senior Vice President of Corporate Communications & IR, at the Tecan Group. His contact number is +41 (0) 44 922 84 30. Email inquiries can be directed to investor@tecan.com, and more information is available on the company’s official website.
Frequently Asked Questions
What is the significance of the CEO transition at Tecan?
The leadership change signifies Tecan's ongoing commitment to growth and innovation as it transitions to new leadership under Monica Manotas.
Who is Monica Manotas?
Monica Manotas is the newly appointed CEO of Tecan, bringing over 20 years of experience from Thermo Fisher Scientific and a strong background in life sciences.
How will this transition affect Tecan's strategy?
Tecan expects the transition to maintain continuity in its strategy, focusing on innovation and market expansion while leveraging Monica's expertise.
When will Tecan release its financial results?
Tecan will publish its financial results for the first half of 2025 on August 12, 2025.
What is Tecan's market position?
Tecan is a leading player in laboratory automation and a key provider of innovative solutions for life science research and clinical diagnostics.
